spironolactone has been researched along with Diabetic Cardiomyopathies in 6 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Diabetic Cardiomyopathies: Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with spironolactone in diabetic patients did not lead to large changes in biomarkers." | 3.01 | Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. ( Brunner-La Rocca, HP; Clark, AL; Cleland, JGF; Cosmi, F; Cuthbert, J; Ferreira, JP; Girerd, N; Heymans, SRB; Mariottoni, B; Pellicori, P; Petutschnigg, J; Rossignol, P; Verdonschot, JAJ; Zannad, F, 2021) |
| "Spironolactone therapy was associated with improvements in diastolic filling profile (Δpeak E wave velocity -4 ± 15 vs." | 2.79 | Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy. ( Haluska, B; Jeffriess, L; Jellis, CL; Jenkins, C; Martin, J; Marwick, TH; Sacre, JW; Wright, J, 2014) |
| "Myocardial fibrosis is one of the key mechanisms and aldosterone is a key mediator of myocardial fibrosis." | 2.78 | Rationale and design of a randomized trial on the impact of aldosterone antagonism on cardiac structure and function in diabetic cardiomyopathy. ( Heritier, S; Leung, DY; Leung, M; Mihailidou, AS; Wong, VW, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Verdonschot, JAJ | 1 |
| Ferreira, JP | 1 |
| Pellicori, P | 1 |
| Brunner-La Rocca, HP | 1 |
| Clark, AL | 1 |
| Cosmi, F | 1 |
| Cuthbert, J | 1 |
| Girerd, N | 1 |
| Mariottoni, B | 1 |
| Petutschnigg, J | 1 |
| Rossignol, P | 1 |
| Cleland, JGF | 1 |
| Zannad, F | 1 |
| Heymans, SRB | 1 |
| Liu, W | 1 |
| Gong, W | 1 |
| He, M | 1 |
| Liu, Y | 1 |
| Yang, Y | 1 |
| Wang, M | 1 |
| Wu, M | 1 |
| Guo, S | 1 |
| Yu, Y | 1 |
| Wang, X | 1 |
| Sun, F | 1 |
| Li, Y | 1 |
| Zhou, L | 1 |
| Qin, S | 1 |
| Zhang, Z | 1 |
| Leung, M | 1 |
| Wong, VW | 1 |
| Heritier, S | 1 |
| Mihailidou, AS | 1 |
| Leung, DY | 1 |
| Ramírez, E | 1 |
| Klett-Mingo, M | 1 |
| Ares-Carrasco, S | 1 |
| Picatoste, B | 1 |
| Ferrarini, A | 1 |
| Rupérez, FJ | 1 |
| Caro-Vadillo, A | 1 |
| Barbas, C | 1 |
| Egido, J | 1 |
| Tuñón, J | 1 |
| Lorenzo, Ó | 1 |
| Jellis, CL | 1 |
| Sacre, JW | 1 |
| Wright, J | 1 |
| Jenkins, C | 1 |
| Haluska, B | 1 |
| Jeffriess, L | 1 |
| Martin, J | 1 |
| Marwick, TH | 1 |
| Nagatomo, Y | 1 |
| Meguro, T | 1 |
| Ito, H | 1 |
| Koide, K | 1 |
| Anzai, T | 1 |
| Fukuda, K | 1 |
| Ogawa, S | 1 |
| Yoshikawa, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure. A Proof of Concept Clinical Trial Within the EU FP 7 (European Union FP7) HOMAGE Programme Heart OMics in AGing "[NCT02556450] | Phase 2 | 528 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for spironolactone and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial.
Topics: Aged; Biomarkers; Blood Proteins; Diabetes Mellitus; Diabetic Cardiomyopathies; Female; Heart Failur | 2021 |
Rationale and design of a randomized trial on the impact of aldosterone antagonism on cardiac structure and function in diabetic cardiomyopathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Ag | 2013 |
Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy.
Topics: Aged; Analysis of Variance; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Dose-R | 2014 |
3 other studies available for spironolactone and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Spironolactone Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Inflammation; Male; Myocardium; | 2018 |
Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes.
Topics: Animals; Apoptosis; Cardiomegaly; Cell Line; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; D | 2013 |
Significance of AT1 receptor independent activation of mineralocorticoid receptor in murine diabetic cardiomyopathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Eplerenone; Male; Mice; Mice, K | 2014 |